Headquartered in San Diego, CA, Biocom California, the leading advocate for life science industry growth worldwide, remarks that Indian biotech companies cannot be ignored. according to an article published in Pharmabiz.
During their visit to India end June, Joseph Panetta, president & CEO of Biocom, and Tim Scott, chairman of Biocom, visited Bangalore and Hyderabad to understand the industry, market prospects, and engage in discussions with biotech companies. They were also looking at potential partnerships and technology transfers for promising medicines as well as for contract research and manufacturing services, besides support with funding for novel drug development initiatives.
Panetta said, “Infectious diseases research and development is the future, and India has its inherent strengths going by the vaccine launches and related new drugs. We will look at the possibilities of disease surveillance, research and development, financing models, supply chain logistic technologies that will give the Indian life science sector a faster connect to garner exposure. We are here to explore partnerships that match innovation with investment.
Besides, we are keen to promote a skilled and diverse pipeline of talent pool to accelerate the growth of life science ecosystems where we would be able to send our teams here and vice versa.
India was preferred over China and for that matter any other South East Asian country because of its IP systems in place. We need to get a good sense of the opportunities that exist which were being explored last year. India cannot be ignored since a sizable opportunity to collaborate exists here.”
(Full disclosure: Biocom California is a client of Amritt Inc.)
